JP2022513098A5 - - Google Patents
Info
- Publication number
- JP2022513098A5 JP2022513098A5 JP2021527918A JP2021527918A JP2022513098A5 JP 2022513098 A5 JP2022513098 A5 JP 2022513098A5 JP 2021527918 A JP2021527918 A JP 2021527918A JP 2021527918 A JP2021527918 A JP 2021527918A JP 2022513098 A5 JP2022513098 A5 JP 2022513098A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- fusion protein
- composition according
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025019347A JP2025081388A (ja) | 2018-11-20 | 2025-02-07 | 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769675P | 2018-11-20 | 2018-11-20 | |
| US62/769,675 | 2018-11-20 | ||
| PCT/IB2019/059945 WO2020104948A1 (en) | 2018-11-20 | 2019-11-19 | Gdf15 analogs and methods for use in decreasing body weight and/or reducing food intake |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025019347A Division JP2025081388A (ja) | 2018-11-20 | 2025-02-07 | 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513098A JP2022513098A (ja) | 2022-02-07 |
| JP2022513098A5 true JP2022513098A5 (https=) | 2022-11-25 |
Family
ID=70773869
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527918A Withdrawn JP2022513098A (ja) | 2018-11-20 | 2019-11-19 | 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法 |
| JP2025019347A Pending JP2025081388A (ja) | 2018-11-20 | 2025-02-07 | 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025019347A Pending JP2025081388A (ja) | 2018-11-20 | 2025-02-07 | 体重減少及び／又は食物摂取量低減に使用するためのｇｄｆ１５類似体及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220315633A1 (https=) |
| EP (1) | EP3883960A4 (https=) |
| JP (2) | JP2022513098A (https=) |
| KR (1) | KR20210094584A (https=) |
| CN (2) | CN113474363A (https=) |
| AU (2) | AU2019383019A1 (https=) |
| BR (1) | BR112021009225A2 (https=) |
| CA (1) | CA3120236A1 (https=) |
| EA (1) | EA202191424A1 (https=) |
| IL (1) | IL283189A (https=) |
| JO (1) | JOP20210111A1 (https=) |
| MX (1) | MX2021005908A (https=) |
| PH (1) | PH12021551119A1 (https=) |
| SG (1) | SG11202104952PA (https=) |
| WO (1) | WO2020104948A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191105A1 (ru) | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
| EP4041281B1 (en) | 2019-10-04 | 2025-11-26 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9131966B2 (en) * | 2013-03-11 | 2015-09-15 | DePuy Synthes Products, Inc. | Vertebral manipulation assembly |
| EP3157947A1 (en) * | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| JP6946304B2 (ja) * | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| EA202191105A1 (ru) * | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
-
2019
- 2019-11-19 EP EP19886438.1A patent/EP3883960A4/en active Pending
- 2019-11-19 CA CA3120236A patent/CA3120236A1/en active Pending
- 2019-11-19 EA EA202191424A patent/EA202191424A1/ru unknown
- 2019-11-19 AU AU2019383019A patent/AU2019383019A1/en not_active Abandoned
- 2019-11-19 KR KR1020217018694A patent/KR20210094584A/ko active Pending
- 2019-11-19 CN CN201980089716.4A patent/CN113474363A/zh active Pending
- 2019-11-19 MX MX2021005908A patent/MX2021005908A/es unknown
- 2019-11-19 SG SG11202104952PA patent/SG11202104952PA/en unknown
- 2019-11-19 BR BR112021009225-0A patent/BR112021009225A2/pt unknown
- 2019-11-19 CN CN202511010324.8A patent/CN121818901A/zh active Pending
- 2019-11-19 WO PCT/IB2019/059945 patent/WO2020104948A1/en not_active Ceased
- 2019-11-19 US US17/309,328 patent/US20220315633A1/en active Pending
- 2019-11-19 JP JP2021527918A patent/JP2022513098A/ja not_active Withdrawn
-
2021
- 2021-05-13 IL IL283189A patent/IL283189A/en unknown
- 2021-05-14 PH PH12021551119A patent/PH12021551119A1/en unknown
- 2021-05-19 JO JOP/2021/0111A patent/JOP20210111A1/ar unknown
-
2025
- 2025-02-07 JP JP2025019347A patent/JP2025081388A/ja active Pending
- 2025-04-02 AU AU2025202337A patent/AU2025202337A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stanislaus et al. | Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin | |
| Tanasescu et al. | Advances in the treatment of relapsing-remitting multiple sclerosis | |
| JP2019065028A5 (https=) | ||
| JP2022513098A5 (https=) | ||
| DK2694087T3 (en) | The treatment of infection with Hepatitis B virus alone or in combination with hepatitis delta virus, and in connection with liver diseases | |
| US8575195B2 (en) | Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent | |
| Deterding et al. | Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta. | |
| IE904035A1 (en) | Medicaments containing as active substance sulphur-containing carboxylic acids and their use in combating retroviruses | |
| Gajofatto | Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date | |
| JP2014114288A5 (https=) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2016516016A5 (https=) | ||
| JP2010529026A5 (https=) | ||
| CA2653201A1 (en) | Compositions and uses of e3-gp19k for treating diabetes | |
| JP2024531151A5 (https=) | ||
| JPH04504570A (ja) | Ｈｉｖ―感染による疾病の治療 | |
| JP2006508039A5 (https=) | ||
| JP2015172060A5 (https=) | ||
| KR20160133479A (ko) | 자가면역 질환의 치료를 위한 조합 요법 | |
| KR20110053327A (ko) | 텔라프레비르 투여 방식 | |
| JP2017519762A5 (https=) | ||
| Wedemeyer et al. | 96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study: 31 | |
| Bridel et al. | Update on multiple sclerosis treatments | |
| JP2022514561A5 (https=) | ||
| Arnason | Long-term experience with interferon beta-1b (Betaferon®) in multiple sclerosis |